Workshop summary: Introduction to rational design of new means for therapeutic modulation of function of the TNF family

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 487-491

  Pfizenmaier, Klaus ^a   Szymkowski, David E ^b  

^a UNIVERSITY OF STUTTGART   (Germany)

^b Xencor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DENOSUMAB; ETANERCEPT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; LUPUS VULGARIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG DESIGN; DRUG POTENTIATION; INFLAMMATION; MOLECULAR LIBRARY; NEOPLASM;

ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; SMALL MOLECULE LIBRARIES; TUMOR NECROSIS FACTORS;

EID: 79954451355     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_50     Document Type: Conference Paper

References (16)

1. (2008) Top 20 Biologics - 2008 Sales of Antibodies R&D Proteins. In R&D Pipeline News, La Merie Business Intelligence (article dated March 9, 2009, available at www.pipelinereview.com)
2. Kaymakcalan Z et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131 (2):308-316
3. Mukai Y et al (2009) Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: Useful information for designing artificial proteo-antagonists. J Biochem 146 (2):167-172
4. McAlpine FE et al (2009) Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 34 (1): 163-177
5. Olleros ML et al (2009) Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette-Guérin(BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Inf Dis 199 (7):1109-1120
6. Zalevsky J et al (2007) Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 (3):1872-1883
7. Driggers EM et al (2008) The exploration of macrocycles for drug discovery-an underexploited structural class. Nat Rev Drug Discov 7 (7):608-624
8. Wu J et al (2009) Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-a production in human whole blood. Bioorg Med Chem Lett 19 (13): 3485-3488
9. Tansey MG, Szymkowski DE (2009) The TNF superfamily in 2009: New pathways, new indications and new drugs. Drug Discov Today 14(23-24):1082-1088
10. Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 Suppl 1, S7
11. Razmara M et al (2009) Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 174 (2):460-474
12. Gerspach J et al (2009) Improving TNF as a cancer therapeutic: Tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors 35 (4):364-372
13. Gerspach J et al (2009) Death ligands designed to kill: Development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl Cell Differ 49:241-273
14. Duiker EW et al (2009) Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 15 (6):2048-2057
15. Labrinidis A et al (2009) Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15 (6):1998-2009
16. Chiang EY et al (2009) Targeted depletion of lymphotoxin-a-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15 (7):766-773